New Therapies Will Transform Treatment of Multiple Myeloma, Says FirstWord in Its New Topical Study Recently Added at MarketPublishers.com
01 Aug 2017 • by Natalie Aster
LONDON – During the recent years, there has been considerable progress in the prognosis for newly diagnosed multiple myeloma (MM) patients.
Whilst the range of currently available treatment options, including Takeda’s Velcade, Celgene’s Revlimid and combination of different therapies, is well established; unmet needs still exist in the market for effective and safe drugs able to deliver durable treatment responses.
At present, AbbVie/Roche’s venetoclax, Karyopharm Therapeutics’ selinexor and Sanofi’s isatuximab form a part of a rich late-stage pipeline.
In the coming years, the novel therapies are anticipated to transform the treatment landscape of the world’s multiple myeloma market.
The new topical research study “Multiple Myeloma: KOL Insight ” worked out by FirstWord offers up-to-date information on the most recent developments and changes in the world’s multiple myeloma treatment landscape and pipeline. It presents an insightful overview of the key marketed drugs, reviews the unmet needs and emerging opportunities, discusses the factors shaping the market. Besides, this publication presents views and opinions of the key opinion leaders (KOLs) across the globe regarding the multiple myeloma market scenario, dynamics and prospects; identifies the most promising products and combinations expected to succeed in the coming years, reviews the pipeline products and gives future projections for the development of the examined field.
Many other topical research studies prepared by this publisher are provided in the FirstWord catalogue at MarketPublishers.com.